248 related articles for article (PubMed ID: 28281872)
1. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity.
Prendergast JM; Galvao da Silva AP; Eavarone DA; Ghaderi D; Zhang M; Brady D; Wicks J; DeSander J; Behrens J; Rueda BR
MAbs; 2017; 9(4):615-627. PubMed ID: 28281872
[TBL] [Abstract][Full Text] [Related]
2. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
Eavarone DA; Al-Alem L; Lugovskoy A; Prendergast JM; Nazer RI; Stein JN; Dransfield DT; Behrens J; Rueda BR
PLoS One; 2018; 13(7):e0201314. PubMed ID: 30052649
[TBL] [Abstract][Full Text] [Related]
3. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
Wang S; Zhou R; Sun F; Li R; Wang M; Wu M
Cancer Lett; 2017 Nov; 409():125-136. PubMed ID: 28923397
[TBL] [Abstract][Full Text] [Related]
4. Sialyl-Tn Polysaccharide A1 as an Entirely Carbohydrate Immunogen: Synthesis and Immunological Evaluation.
Shi M; Kleski KA; Trabbic KR; Bourgault JP; Andreana PR
J Am Chem Soc; 2016 Nov; 138(43):14264-14272. PubMed ID: 27726393
[TBL] [Abstract][Full Text] [Related]
5. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.
Loureiro LR; Sousa DP; Ferreira D; Chai W; Lima L; Pereira C; Lopes CB; Correia VG; Silva LM; Li C; Santos LL; Ferreira JA; Barbas A; Palma AS; Novo C; Videira PA
Sci Rep; 2018 Aug; 8(1):12196. PubMed ID: 30111774
[TBL] [Abstract][Full Text] [Related]
6. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.
Starbuck K; Al-Alem L; Eavarone DA; Hernandez SF; Bellio C; Prendergast JM; Stein J; Dransfield DT; Zarrella B; Growdon WB; Behrens J; Foster R; Rueda BR
Oncotarget; 2018 May; 9(33):23289-23305. PubMed ID: 29796189
[TBL] [Abstract][Full Text] [Related]
8. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-sTn monoclonal antibody 3P9 Inhibits human xenografted colorectal carcinomas.
An Y; Han W; Chen X; Zhao X; Lu D; Feng J; Yang D; Song L; Yan X
J Immunother; 2013 Jan; 36(1):20-8. PubMed ID: 23211624
[TBL] [Abstract][Full Text] [Related]
10. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
11. Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing.
Trabbic KR; Kleski KA; Shi M; Bourgault JP; Prendergast JM; Dransfield DT; Andreana PR
Cancer Immunol Immunother; 2018 Sep; 67(9):1437-1447. PubMed ID: 30030557
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
13. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
14. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
[TBL] [Abstract][Full Text] [Related]
15. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Al-Alem L; Prendergast JM; Clark J; Zarrella B; Zarrella DT; Hill SJ; Growdon WB; Pooladanda V; Spriggs DR; Cramer D; Elias KM; Nazer RI; Skates SJ; Behrens J; Dransfield DT; Rueda BR
J Ovarian Res; 2024 Apr; 17(1):71. PubMed ID: 38566237
[TBL] [Abstract][Full Text] [Related]
16. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.
Julien S; Picco G; Sewell R; Vercoutter-Edouart AS; Tarp M; Miles D; Clausen H; Taylor-Papadimitriou J; Burchell JM
Br J Cancer; 2009 Jun; 100(11):1746-54. PubMed ID: 19436292
[TBL] [Abstract][Full Text] [Related]
17. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
18. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
19. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
